Medulloblastoma Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Last Updated: 2020-05-29
Originally Posted: 2017-05-15

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Last Updated: 2020-05-29
Originally Posted: 2018-05-15

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
Last Updated: 2020-05-28
Originally Posted: 2017-07-10

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Last Updated: 2020-05-28
Originally Posted: 2017-07-06

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Last Updated: 2020-05-28
Originally Posted: 2017-07-10

PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Last Updated: 2020-05-28
Originally Posted: 2017-07-10

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Last Updated: 2020-05-28
Originally Posted: 2017-07-10

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Last Updated: 2020-05-28
Originally Posted: 2017-07-25

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Last Updated: 2020-05-28
Originally Posted: 2018-10-05

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
Last Updated: 2020-05-27
Originally Posted: 2015-02-09

Rare CNS Tumors Outcomes &Risk
Last Updated: 2020-05-23
Originally Posted: 2017-08-15

Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults With Recurrent Medulloblastoma
Last Updated: 2020-05-15
Originally Posted: 2020-03-17

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Last Updated: 2020-05-14
Originally Posted: 2014-03-13

Volitinib in Treating Participants With Recurrent or Refractory Primary CNS Tumors
Last Updated: 2020-05-14
Originally Posted: 2018-07-24

Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
Last Updated: 2020-05-12
Originally Posted: 2012-07-30

Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma
Last Updated: 2020-05-04
Originally Posted: 2011-05-17

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Last Updated: 2020-05-04
Originally Posted: 2013-06-10

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
Last Updated: 2020-04-30
Originally Posted: 2016-01-04

AflacST1901: Peds WP1066
Last Updated: 2020-04-29
Originally Posted: 2020-04-02

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
Last Updated: 2020-04-29
Originally Posted: 2016-03-25

Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers
Last Updated: 2020-04-17
Originally Posted: 2017-05-31

HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Last Updated: 2020-04-02
Originally Posted: 2018-03-21

A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
Last Updated: 2020-04-01
Originally Posted: 2016-04-08

PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma
Last Updated: 2020-04-01
Originally Posted: 2017-09-27

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
Last Updated: 2020-03-10
Originally Posted: 2019-07-11

StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord
Last Updated: 2020-02-25
Originally Posted: 2019-06-17

Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
Last Updated: 2020-02-24
Originally Posted: 2018-03-20

Fimepinostat in Treating Brain Tumors in Children and Young Adults
Last Updated: 2020-02-24
Originally Posted: 2019-03-26

EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Last Updated: 2020-02-21
Originally Posted: 2018-08-15

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Last Updated: 2020-02-21
Originally Posted: 2019-11-26

Phase I Study of APX005M in Pediatric CNS Tumors
Last Updated: 2020-02-20
Originally Posted: 2017-12-15

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Last Updated: 2020-02-20
Originally Posted: 2018-10-09

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Last Updated: 2020-02-20
Originally Posted: 2019-04-09

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Last Updated: 2020-02-17
Originally Posted: 2018-02-09

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
Last Updated: 2020-02-07
Originally Posted: 2019-04-01

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Last Updated: 2020-02-03
Originally Posted: 2012-01-04

DOTATOC PET/CT for Imaging NET Patients
Last Updated: 2020-01-21
Originally Posted: 2018-06-08

Components of Social Functioning in Survivors of Pediatric Brain Tumors
Last Updated: 2020-01-17
Originally Posted: 2017-11-28

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
Last Updated: 2019-11-20
Originally Posted: 2016-04-27

Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Last Updated: 2019-10-24
Originally Posted: 2017-02-02

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Last Updated: 2019-10-17
Originally Posted: 2019-08-02

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer
Last Updated: 2019-10-12
Originally Posted: 2019-04-30

Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
Last Updated: 2019-09-23
Originally Posted: 2017-12-05

Study of Stored Tumor Samples in Young Patients With Brain Tumors
Last Updated: 2019-09-20
Originally Posted: 2009-05-09

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
Last Updated: 2019-09-11
Originally Posted: 2019-09-04

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
Last Updated: 2019-09-05
Originally Posted: 2015-12-27

Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
Last Updated: 2019-08-20
Originally Posted: 2016-11-02

Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors
Last Updated: 2019-06-21
Originally Posted: 2016-09-07

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
Last Updated: 2019-06-19
Originally Posted: 2017-09-01

Methionine PET/CT Studies In Patients With Cancer
Last Updated: 2019-06-17
Originally Posted: 2009-02-09

An International Prospective Trial On Medulloblastoma (mb) In Children Older Than 3 To 5 Years With Wnt Biological Profile (pnet 5 Mb – Lr And Pnet 5 Mb – Wnt-hr), Average-risk Biological Profile (pnet 5 Mb -sr), Or Tp53 Mutation And Registry For Mb Occurring In The Context Of Genetic Predisposition
Last Updated: 2019-06-12
Originally Posted: 2019-06-12

Diffuse Brainstem Glioma Tumour Study: developing new treatment strategies for Diffuse Pontine Glioma
Last Updated: 2019-05-02
Originally Posted: 2012-10-31

A Phase Ii Study Of Metronomic And Targeted Anti-angiogenesis Therapy For Children With Recurrent/progressive Medulloblastoma
Last Updated: 2019-04-04
Originally Posted: 2019-04-04

A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
Last Updated: 2019-02-18
Originally Posted: 2018-11-05

An International Prospective Trial On Medulloblastoma (mb) In Children Older Than 3 To 5 Years With Wnt Biological Profile (pnet 5 Mb – Lr And Pnet 5 Mb – Wnt-hr), Average-risk Biological Profile (pnet 5 Mb -sr), Or Tp53 Mutation And Registry For Mb Occurring In The Context Of Genetic Predisposition
Last Updated: 2019-02-13
Originally Posted: 2019-02-13

A study to evaluate the safety,tolerability and pharmacokinetics of ACT001 in children with advanced brain and solid tumors
Last Updated: 2018-11-28
Originally Posted: 2018-11-05

Study of Tomotherapy HD in Medulloblastoma
Last Updated: 2018-09-16
Originally Posted: 2018-09-16

Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas
Last Updated: 2018-07-03
Originally Posted: 2013-05-16

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Last Updated: 2018-04-13
Originally Posted: 2004-08-04

A Phase 2 Clinical Study Of Pomalidomide (cc-4047) Monotherapy For Children And Young Adults With Recurrent Or Progressive Primary Brain Tumors.
Last Updated: 2018-01-30
Originally Posted: 2018-01-30

International HIT-MED Registry (I-HIT-MED)
Last Updated: 2017-10-17
Originally Posted: 2015-02-04

A Phase 2 Clinical Study Of Pomalidomide (cc-4047) Monotherapy For Children And Young Adults With Recurrent Or Progressive Primary Brain Tumors.
Last Updated: 2017-09-26
Originally Posted: 2017-09-26

Phase Ib /ii Clinical Trial Of Nivolumab Monotherapy And Nivolumab In Combination With Ipilimumab In Pediatric Subjects With High Grade Primary Cns Malignancies
Last Updated: 2017-08-01
Originally Posted: 2017-08-01

A Phase 2 Clinical Study Of Pomalidomide (cc-4047) Monotherapy For Children And Young Adults With Recurrent Or Progressive Primary Brain Tumors.
Last Updated: 2017-07-27
Originally Posted: 2017-07-27

Phase Ib /ii Clinical Trial Of Nivolumab Monotherapy And Nivolumab In Combination With Ipilimumab In Pediatric Subjects With High Grade Primary Cns Malignancies
Last Updated: 2017-07-11
Originally Posted: 2017-07-11

Phase Ib /ii Clinical Trial Of Nivolumab Monotherapy And Nivolumab In Combination With Ipilimumab In Pediatric Subjects With High Grade Primary Cns Malignancies
Last Updated: 2017-06-19
Originally Posted: 2017-06-19

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
Last Updated: 2017-05-05
Originally Posted: 2014-02-07

Phase Ib /ii Clinical Trial Of Nivolumab Monotherapy And Nivolumab In Combination With Ipilimumab In Pediatric Subjects With High Grade Primary Cns Malignancies
Last Updated: 2017-04-28
Originally Posted: 2017-04-28

Phase Ib /ii Clinical Trial Of Nivolumab Monotherapy And Nivolumab In Combination With Ipilimumab In Pediatric Subjects With High Grade Primary Cns Malignancies
Last Updated: 2017-04-17
Originally Posted: 2017-04-17

An International Prospective Study On Clinically Standard-risk Medulloblastoma In Children Older Than 3 To 5 Years With Low-risk Biological Profile (pnet 5 Mb - Lr) Or Average-risk Biological Profile (pnet 5 Mb -sr)
Last Updated: 2016-10-21
Originally Posted: 2016-10-21

Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma
Last Updated: 2016-06-08
Originally Posted: 2013-12-30

An International Prospective Study On Clinically Standard-risk Medulloblastoma In Children Older Than 3 To 5 Years With Low-risk Biological Profile (pnet 5 Mb - Lr) Or Average-risk Biological Profile (pnet 5 Mb -sr)
Last Updated: 2016-03-09
Originally Posted: 2016-03-09

Phase I/ii Open Label, Dose Escalation Trial To Determine The Mtd, Safety, Pk And Efficacy Of Afatinib Monotherapy In Children Aged ≥1 Year To <18 Years With Recurrent/refractory Neuroectodermal Tumours, Rhabdomyosarcoma And/or Other Solid Tumours With Known Erbb Pathway Deregulation Regardless Of Tumour Histology
Last Updated: 2016-02-15
Originally Posted: 2016-02-15

Phase I Open Label, Dose Escalation Trial To Determine The Mtd, Safety, Pk And Efficacy Of Afatinib Monotherapy In Children Aged 2 Years To <18 Years With Recurrent/refractory Neuroectodermal Tumours, Rhabdomyosarcoma And/or Other Solid Tumours With Known Erbb Pathway Deregulation Regardless Of Tumour Histology
Last Updated: 2015-11-23
Originally Posted: 2015-11-23

An International Prospective Study On Clinically Standard-risk Medulloblastoma In Children Older Than 3 Years With Low-risk Biological Profile (pnet 5 Mb-lr) Or Average-risk Biological Profile (pnet 5 Mb-sr) - Siop Pnet 5 Medulloblastoma
Last Updated: 2015-11-04
Originally Posted: 2015-11-04

An International Prospective Study On Clinically Standard-risk Medulloblastoma In Children Older Than 3 To 5 Years With Low-risk Biological Profile (pnet 5 Mb - Lr) Or Average-risk Biological Profile (pnet 5 Mb -sr)
Last Updated: 2015-07-31
Originally Posted: 2015-07-31

A Phase Ii Study Of Metronomic And Targeted Anti-angiogenesis Therapy For Children With Recurrent/progressive Medulloblastoma
Last Updated: 2015-06-16
Originally Posted: 2015-06-16

A Phase Ii Study Of Metronomic And Targeted Anti-angiogenesis Therapy For Children With Recurrent/progressive Medulloblastoma
Last Updated: 2015-06-11
Originally Posted: 2015-06-11

An International Prospective Trial On Medulloblastoma (mb) In Children Older Than 3 To 5 Years With Wnt Biological Profile (pnet 5 Mb – Lr And Pnet 5 Mb – Wnt-hr), Average-risk Biological Profile (pnet 5 Mb -sr), Or Tp53 Mutation And Registry For Mb Occurring In The Context Of Genetic Predisposition
Last Updated: 2015-05-22
Originally Posted: 2015-05-22

An International Prospective Study On Clinically Standard-risk Medulloblastoma In Children Older Than 3 To 5 Years With Low-risk Biological Profile (pnet 5 Mb - Lr) Or Average-risk Biological Profile (pnet 5 Mb -sr)
Last Updated: 2015-03-31
Originally Posted: 2015-03-31

Phase I/ii Open Label, Dose Escalation Trial To Determine The Mtd, Safety, Pk And Efficacy Of Afatinib Monotherapy In Children Aged ≥1 Year To <18 Years With Recurrent/refractory Neuroectodermal Tumours, Rhabdomyosarcoma And/or Other Solid Tumours With Known Erbb Pathway Deregulation Regardless Of Tumour Histology
Last Updated: 2015-02-19
Originally Posted: 2015-02-19

Phase I/ii Open Label, Dose Escalation Trial To Determine The Mtd, Safety, Pk And Efficacy Of Afatinib Monotherapy In Children Aged ≥ 1 Year To <18 Years With Recurrent/refractory Neuroectodermal Tumours, Rhabdomyosarcoma And/or Other Solid Tumours With Known Erbb Pathway Deregulation Regardless Of Tumour Histology
Last Updated: 2015-02-11
Originally Posted: 2015-02-11

An International Prospective Study On Clinically Standard-risk Medulloblastoma In Children Older Than 3 To 5 Years With Low-risk Biological Profile (pnet 5 Mb - Lr) Or Average-risk Biological Profile (pnet 5 Mb -sr)
Last Updated: 2015-01-07
Originally Posted: 2015-01-07

A Phase Ii Study Of Metronomic And Targeted Anti-angiogenesis Therapy For Children With Recurrent/progressive Medulloblastoma
Last Updated: 2014-03-26
Originally Posted: 2014-03-26

An International Prospective Study On Clinically Standard-risk Medulloblastoma In Children Older Than 3 To 5 Years With Low-risk Biological Profile (pnet 5 Mb - Lr) Or Average-risk Biological Profile (pnet 5 Mb -sr)
Last Updated: 2014-01-09
Originally Posted: 2014-01-09

An International Prospective Study On Clinically Standard-risk Medulloblastoma In Children Older Than 3 To 5 Years With Low-risk Biological Profile (pnet 5 Mb - Lr) Or Average-risk Biological Profile (pnet 5 Mb -sr)
Last Updated: 2013-12-10
Originally Posted: 2013-12-10

Phase I / Ii Study Of Sequential High-dose Chemotherapy With Stem Cell Support In Children Younger Than 5 Years Of Age With High-risk Medulloblastoma
Last Updated: 2013-05-22
Originally Posted: 2013-05-22

A Phase Ii Study Of Metronomic And Targeted Anti-angiogenesis Therapy For Children With Recurrent/progressive Medulloblastoma
Last Updated: 2012-04-20
Originally Posted: 2012-04-20

A Phase Ii Study Of Metronomic And Targeted Anti-angiogenesis Therapy For Children With Recurrent/progressive Medulloblastoma
Last Updated: 2011-04-12
Originally Posted: 2011-04-12

Estudio Fase Ii No Aleatorizado De Tratamiento Con Temozolamida Combinada Con Topotecan Para Neuroblastoma Y Otros Tumores Sólidos Pediátricos En Situación De Recaída O Progresión. "phase 2 Single-arm Studies Of Temozolamide Incombination With Topotecan In Refractory And Relapsed Neuroblastoma And Other Paediatric Solid Tumours"
Last Updated: 2010-03-03
Originally Posted: 2010-03-03

Acns0331 A Study Evaluating Limited Target Volume Boost Irradiation And Reduced Dose Craniospinal Radiotherapy (18.00 Gy) And Chemotherapy In Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase Iii Double Randomized Trial. An Intergroup Study For Participation By Cog And The Dutch Childhood Oncology Group – Skion (stichting Kinderoncologie Nederland)
Last Updated: 2009-08-18
Originally Posted: 2009-08-18

Phase 2 Single-arm Studies Of Temozolomide In Combination With Topotecan In Refractory Or Relapsing Neuroblastoma And Other Pediatric Solid Tumours.
Last Updated: 2009-07-08
Originally Posted: 2009-07-08

Phase 2 Single-arm Studies Of Temozolomide In Combination With Topotecan In Refractory Or Relapsing Neuroblastoma And Other Pediatric Solid Tumours.
Last Updated: 2008-05-16
Originally Posted: 2008-05-16

Phase 2 Single-arm Studies Of Gemcitabine In Combination With Oxaliplatin In Refractory And Relapsed Pediatric Solid Tumors. (etude De Phase Ii De L’association Gemcitabine - Oxaliplatine « Gemox » Chez Les Patients Porteurs D’une Tumeur Solide Maligne Réfractaire Ou En Rechute).
Last Updated: 2007-05-10
Originally Posted: 2007-05-10

Phase 2 Single-arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-grade Glioma
Last Updated: 2006-12-29
Originally Posted: 2006-12-29